Space & Satellites
Varda and United Therapeutics Partner for Orbital Drug Manufacturing
Varda Space Industries and United Therapeutics collaborate to develop microgravity-enabled treatments for rare pulmonary diseases using orbital pharmaceutical manufacturing.

On May 13, 2026, Varda Space Industries and United Therapeutics Corporation announced a landmark collaboration to manufacture pharmaceuticals in low Earth orbit (LEO). The partnership focuses on developing microgravity-enabled treatments for rare pulmonary diseases, marking a significant milestone in the intersection of commercial spaceflight and biotechnology.
According to the official press release, this initiative represents the first-ever commercial research collaboration focused on space-based drug formulation aimed at producing tangible therapies for patients on Earth. By utilizing Varda’s automated reentry capsules, the companies aim to process small-molecule medicines in space and return them to Earth for clinical evaluation and eventual patient use.
This collaboration signals a major shift from traditional, government-funded research conducted on the International Space Station (ISS) to a dedicated commercial supply chain model. By leveraging the unique physics of zero gravity, the partnership strives to revolutionize how life-saving therapies are formulated and delivered.
The Science of Microgravity Manufacturing
The core advantage of orbital pharmaceutical manufacturing lies in the absence of Earth’s gravitational pull. On Earth, gravity induces sedimentation and convection currents that can disrupt how molecules assemble during the manufacturing process. In the weightless environment of space, these disruptive forces vanish.
According to the provided research report, this microgravity environment allows molecules to assemble more slowly and uniformly. The result is the creation of highly ordered crystal structures, known as polymorphs, that are either significantly purer or entirely impossible to synthesize in a terrestrial laboratory.
Targeted Pharmaceutical Benefits
By exploiting microgravity’s influence on molecular structure and crystallization, Varda and United Therapeutics hope to achieve several critical breakthroughs in drug formulation. The targeted benefits of this orbital processing include:
- Improved Bioavailability: Allowing medications to dissolve and be absorbed more consistently by the human body.
- Enhanced Stability: Extending the shelf life of medications and potentially reducing the need for expensive, complex cold-chain storage.
- Advanced Delivery Methods: Enabling the creation of new inhaled or controlled-release therapies.
- Targeted Efficiency: Formulating drugs that deliver active ingredients more efficiently to the intended site of action.
Commercializing Orbital Infrastructure
Varda Space Industries, an El Segundo, California-based startup founded in 2021 and backed by Founders Fund, is pioneering the infrastructure required for this endeavor. Unlike traditional microgravity research on the ISS, which is frequently bottlenecked by crew schedules, contamination risks, and long wait times for return flights, Varda utilizes automated, free-flying “W-series” reentry capsules.
These capsules are designed to launch as secondary payloads, often aboard SpaceX missions. Once in orbit, they autonomously process materials before returning the finished products to Earth, landing at designated recovery sites such as the Australian desert.
Industry Perspectives
Leadership from both companies emphasized the transformative potential of moving pharmaceutical development into orbit. In the official announcement, Varda Space Industries CEO Will Bruey highlighted the unique advantages of their platform:
“Microgravity gives us a fundamentally different environment to manufacture pharmaceuticals that are otherwise impossible on Earth. Our collaboration with United Therapeutics strives to pioneer a new era in clinical development by completing the bridge from microgravity science to patient benefit on Earth.”
Martine Rothblatt, Ph.D., Chairperson and CEO of United Therapeutics, noted in the release that the collaboration will allow the biotechnology firm to explore how space-based manufacturing could contribute to significant improvements for rare pulmonary disease treatments.
Michael Reilly, Chief Strategy Officer of Varda Space Industries, underscored the commercial novelty of the venture, pointing out the historical limitations of space research:
“We’ve been learning from space for years, but I can’t name anything manufactured in space, brought down to Earth, and sold. So that is a first, or it will be a first.”
Financial Context and Next Steps
United Therapeutics Corporation (Nasdaq: UTHR) is a biotechnology giant with a market capitalization of $24.69 billion, specializing in innovative therapies for life-threatening conditions like pulmonary arterial hypertension. Following the announcement of the collaboration, industry reports noted that United Therapeutics’ stock was trading near its 52-week high of $609.35, reflecting strong investor confidence in the company’s innovative pipeline.
While the specific compounds and exact financial terms of the deal remain undisclosed, the agreement stipulates that United Therapeutics is compensating Varda to help identify new crystal forms of its existing drugs.
The timeline for this orbital manufacturing initiative is advancing rapidly. According to the research report, a launch carrying United Therapeutics’ drug samples aboard a Varda capsule could occur as early as early 2027. Once the capsules return to Earth, scientists at United Therapeutics will rigorously test the newly formed polymorphs to evaluate their enhanced properties.
AirPro News analysis
We observe that this partnership answers a long-standing question in the aerospace sector: whether orbital drug manufacturing can successfully transition from a scientific curiosity to a viable, scalable business model. For over two decades, microgravity research has been largely confined to the ISS, yielding promising scientific results that rarely translated into commercial manufacturing pipelines due to logistical and financial constraints.
As launch costs continue to decrease and automated satellite technology matures, space-based manufacturing is rapidly emerging as a practical tool for terrestrial industries. If Varda and United Therapeutics are successful in returning commercially viable, enhanced pharmaceuticals from orbit, it could pave the way for a new era of space-enabled medicine, fundamentally altering the economic landscape of both the commercial space sector and the global biotechnology industry.
Frequently Asked Questions (FAQ)
What is the goal of the Varda and United Therapeutics collaboration?
The partnership aims to develop improved formulations of treatments for rare pulmonary diseases by manufacturing small-molecule medicines in the microgravity environment of low Earth orbit.
How does microgravity improve drug manufacturing?
In space, the absence of gravity eliminates sedimentation and convection currents. This allows molecules to assemble more slowly and uniformly, creating highly ordered crystal structures (polymorphs) that can improve a drug’s bioavailability, stability, and delivery methods.
When will the first manufacturing mission launch?
A launch carrying United Therapeutics’ drug samples aboard a Varda reentry capsule is projected to happen as early as early 2027.
How do the drugs return to Earth?
Varda utilizes automated “W-series” reentry capsules that process the materials in orbit and then reenter the Earth’s atmosphere, landing at designated recovery sites such as the Australian desert.
Sources
Photo Credit: Varda Space Industries
Space & Satellites
Firefly Aerospace Advances Esrange Launch Complex for 2028 Orbital Debut
Firefly Aerospace and SSC Space complete infrastructure at Esrange Space Center, targeting first orbital launch in 2028.

Firefly Aerospace and the Swedish Space Corporation (SSC Space) have completed initial infrastructure and secured transatlantic regulatory frameworks to advance pad construction at Launch Complex 3C at Sweden’s Esrange Space Center, targeting a first orbital launch in 2028.
Announced in a June 30, 2026, press release, the milestone establishes a foundation for dedicated orbital launch capabilities from mainland Europe. The partnership will utilize Firefly’s Alpha launch vehicle to serve European commercial customers and the Swedish Armed Forces, expanding access to space for allied nations.
Infrastructure and regulatory progress
The companies have completed several key infrastructure projects at Launch Complex 3C to support the upcoming orbital missions. The finalized facilities include a launch control center, a payload processing facility, and a launch vehicle integration building. The site also features newly installed tracking and control systems, alongside dedicated security and storage facilities.
The physical construction aligns with recent diplomatic agreements designed to facilitate international commercial space operations. In April 2026, the Swedish National Space Agency (SNSA) and the U.S. Federal Aviation Administration (FAA) signed a Memorandum of Cooperation to streamline the launch licensing process and establish a shared understanding of commercial space regulations. This agreement builds upon a broader framework, making Sweden the sixth country to sign a Technology Safeguards Agreement with the United States.
Defense applications and payload capabilities
The development at Esrange Space Center carries direct implications for European defense logistics. SSC Space recently signed an agreement valued at SEK 209 million with the Swedish Defense Materiel Administration (FMV). The contract is structured to provide the Swedish Armed Forces with dedicated satellite launch capabilities from the domestic spaceport.
Missions from Launch Complex 3C will utilize the Firefly Alpha, a two-stage launch vehicle capable of delivering a 1,000-kilogram payload to Low Earth Orbit (LEO). The deployment of an American rocket from European soil represents a specific operational strategy for the Texas-based manufacturer.
“We’re proud to partner with SSC Space and work collaboratively with U.S. and Swedish agencies to provide European customers with a dedicated orbital launch capability using our flight-proven Alpha rocket. Our ‘launch as a franchise’ model provides our nation and allies with the launch site diversification required for resilient, responsive space missions.”
The statement from Firefly Aerospace CEO Jason Kim highlights the company’s focus on global launch expansion, utilizing the Swedish site as the starting point for its international franchise model.
AirPro News analysis
We view Firefly’s “launch as a franchise” model as a strategic pivot in the commercial space sector, moving away from centralized domestic launch sites toward distributed, allied-nation launch capabilities. The SEK 209 million defense agreement underscores the growing military reliance on commercial launch providers for responsive space access. By establishing a physical and regulatory foothold at Esrange Space Center, Firefly positions the Alpha rocket to capture a significant share of the emerging European small-lift market, while simultaneously offering the U.S. and its allies redundant launch options outside of traditional North American spaceports.
Sources: Firefly Aerospace
Photo Credit: Firefly Aerospace
Space & Satellites
Rocket Lab to Acquire Iridium Communications for $8 Billion
Rocket Lab agrees to acquire Iridium Communications for ~$8B, combining launch capabilities with Iridium’s LEO satellite network.

Rocket Lab Corporation (Nasdaq: RKLB) has entered into a definitive agreement to acquire satellite operator Iridium Communications Inc. (Nasdaq: IRDM) in a cash and stock transaction valuing the company at approximately $8.0 billion. The deal, announced on June 29, 2026, transforms the launch provider into a fully vertically integrated space enterprise with an immediate foothold in global satellite connectivity.
Under the terms detailed in a joint press release, Iridium stockholders will receive $54.00 per share, consisting of $27.00 in cash and a portion of Rocket Lab common stock based on a collar band exchange ratio between $67.50 and $112.50. The Acquisitions merges Rocket Lab’s launch and spacecraft Manufacturing capabilities with Iridium’s globally harmonized L-band spectrum and established Low Earth Orbit (LEO) satellite network, which currently supports 2.55 million active subscribers worldwide.
Strategic integration and market expansion
The transaction positions Rocket Lab to capture a larger share of the space-based applications Market-Analysis, including satellite Internet of Things (IoT), Direct-to-Device (D2D) communications, and Positioning, Navigation, and Timing (PNT) services. Iridium reported $871.7 million in revenue and $495 million in Operational EBITDA for 2025, providing Rocket Lab with a highly profitable, established communications business operating at a 57 percent margin.
A primary operational synergy of the merger is the elimination of third-party launch costs for the deployment and replenishment of the Iridium NEXT constellation. Rocket Lab intends to utilize its Electron and upcoming Neutron launch vehicles to guarantee orbital access and maintain continuity of service for the network.
Sir Peter Beck, Founder and CEO of Rocket Lab, described the agreement as a defining moment for the space industry and the start of a new era of strategic growth for both companies.
“By marrying Iridium’s deep heritage, trusted infrastructure, and highly sought-after spectrum with Rocket Lab’s extensive and proven launch and manufacturing capabilities, we have the capability to unlock entirely new markets,” Beck stated. “We will go far beyond maintaining a legacy; we are going to build upon it to pioneer next-generation space applications and deliver sought-after capabilities to existing and new customers.”
Accelerating next-generation satellite services
The acquisition occurs as the space and terrestrial communications sectors increasingly converge. Rocket Lab plans to leverage the combined company’s resources to accelerate the development of Iridium’s next-generation constellation. This includes advancing D2D services targeted at United States national security and emergency response sectors, where traditional terrestrial networks may be unavailable or compromised.
Iridium CEO Matt Desch noted that critical services will increasingly depend on space-based capabilities as the industry evolves. He emphasized that success in the sector requires bringing innovations to space quickly and sustaining them efficiently over time.
“We’re excited about being able to accelerate the next generation of IoT, aviation, maritime, PNT, and national security capabilities, and pursue new innovative applications as part of Rocket Lab,” Desch said.
To fund the cash component of the transaction, Deutsche Bank and Wells Fargo have committed a $3.6 billion, 364-day senior secured bridge term loan facility. The transaction is expected to close in mid-2027, pending approval from stockholders and regulatory authorities, including the U.S. Securities and Exchange Commission (SEC).
AirPro News analysis
We view this $8.0 billion acquisition as a structural shift in the aerospace sector, moving away from the traditional separation of launch providers and satellite operators. By bringing Iridium in-house, Rocket Lab secures an anchor tenant for its Neutron launch vehicle while simultaneously capturing the high-margin recurring revenue of Iridium’s subscriber base.
The timing is particularly notable given the tightening availability of global launch capacity. Owning internal launch capabilities insulates the Iridium network from external supply chain bottlenecks and launch delays. Controlling both the manufacturing of the spacecraft and the launch vehicle also allows for deep vertical integration, potentially lowering the capital expenditure required for future constellation upgrades and D2D network deployments.
Sources: Iridium Communications Inc. / Rocket Lab Corporation
Photo Credit: Rocket Lab Corporation
Space & Satellites
Firefly Aerospace Acquires Space-ng for Autonomous Navigation
Firefly Aerospace acquires Space-ng Inc. to integrate AI vision navigation into its Blue Ghost and Elytra spacecraft programs.

Firefly Aerospace (Nasdaq: FLY) has acquired the artificial intelligence and vision navigation developer Space-ng Inc., integrating autonomous guidance capabilities into its lunar and orbital spacecraft portfolio. The Acquisitions, announced on June 25, 2026, from Firefly headquarters in Cedar Park, Texas, brings critical optical navigation technology in-house as the company scales its deep space operations.
In a press release issued on June 25, 2026, Firefly Aerospace confirmed that Space-ng will be fully integrated into its operations. The move secures the hardware and software systems necessary for spacecraft to perform rendezvous, docking, and hazard avoidance maneuvers without relying on the Global Navigation Satellite System (GNSS) or GPS.
Integration into Blue Ghost and Elytra programs
Space-ng’s spacecraft software, high-resolution cameras, and AI compute hardware will be incorporated directly into Firefly’s Blue Ghost lunar landers and Elytra orbital vehicles. The two companies previously collaborated on Blue Ghost Mission 1, which landed in the Mare Crisium basin on the Moon on March 2, 2025. During that descent, the lander utilized Space-ng vision Navigation software to determine position and attitude, detect hazardous terrain, and autonomously redirect the vehicle in real time.
Firefly Aerospace CEO Jason Kim stated that the technology proved itself during the descent, allowing the lander to execute two hazard avoidance maneuvers and safely touch down.
“This acquisition represents a strategic investment in both the experienced team and technologies from Space-ng that will continue to play a pivotal role in advancing autonomous space operations,” Kim said. “We’re proud to welcome Space-ng to the Firefly team as we work towards enabling regular, repeatable access to the Moon and beyond.”
Expanding mission manifest and leadership changes
Firefly is preparing for a growing manifest that relies on this integrated technology. The schedule includes three additional lunar missions under the National Aeronautics and Space Administration (NASA) Commercial Lunar Payload Services (CLPS) initiative. The company will also support the NASA MoonFall mission and a space domain awareness mission for the Defense Innovation Unit (DIU).
Following the acquisition, Space-ng co-founder and CEO Ethan Rublee transitions to the role of Chief Engineer of Software at Firefly Aerospace. Financial terms of the transaction were not disclosed. J.P. Morgan Securities LLC served as the exclusive financial advisor to Firefly Aerospace for the acquisition.
AirPro News analysis
We view this acquisition as a necessary vertical integration step for Firefly Aerospace as the complexity of its mission manifest increases. Relying on third-party vendors for mission-critical autonomous navigation introduces Supply-Chain and integration risks, particularly for lunar surface operations where real-time hazard avoidance is the difference between mission success and failure. By bringing Space-ng in-house, Firefly secures proprietary control over the optical navigation systems required for its upcoming CLPS and DIU contracts, positioning the company to compete more aggressively for government and commercial deep-space payloads that demand high-precision, GPS-denied navigation.
Sources: Firefly Aerospace
Photo Credit: Firefly Aerospace
-
Aircraft Orders & Deliveries2 days agoSMBC Sells $2B Aircraft Loan Portfolio After Air Lease Acquisition
-
Aircraft Orders & Deliveries6 days agoUSC Aero Acquires Five Lufthansa A340-600s for Fleet and Parts
-
Regulations & Safety5 days agoLight-Sport Aircraft Strikes CITIC Tower in Beijing
-
MRO & Manufacturing3 days agoSeAH Besteel Opens Texas Superalloy Plant in H2 2026
-
Defense & Military5 days agoLockheed Martin NXGB Hypersonic Glide Body Program Launch
